BR112022012789A2 - Homólogo de proteína, quito-oligossacarídeo, composição farmacêutica, método de tratamento ou prevenção, ácido nucleico sintético ou recombinante e uso de um homólogo de proteína - Google Patents
Homólogo de proteína, quito-oligossacarídeo, composição farmacêutica, método de tratamento ou prevenção, ácido nucleico sintético ou recombinante e uso de um homólogo de proteínaInfo
- Publication number
- BR112022012789A2 BR112022012789A2 BR112022012789A BR112022012789A BR112022012789A2 BR 112022012789 A2 BR112022012789 A2 BR 112022012789A2 BR 112022012789 A BR112022012789 A BR 112022012789A BR 112022012789 A BR112022012789 A BR 112022012789A BR 112022012789 A2 BR112022012789 A2 BR 112022012789A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein homolog
- oligosaccharide
- present
- provides
- chito
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
HOMÓLOGO DE PROTEÍNA, QUITO-OLIGOSSACARÍDEO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE TRATAMENTO OU PREVENÇÃO, ÁCIDO NUCLEICO SINTÉTICO OU RECOMBINANTE E USO DE UM HOMÓLOGO DE PROTEÍNA. A presente invenção proporciona moléculas terapêuticas para combater sepse. A presente invenção proporciona proteínas capazes de aprimorar a sobrevivência através de imunomodulação em pós-septicemia em mamíferos e oligossacarídeos, capazes de imunomodular inflamação em um mamífero. A presente invenção proporciona homólogo de proteínas de HSP70 humano derivado a partir de nematoide Setaria digitata e suas formas recombinantes e oligossacarídeos e o papel das mesmas em imunomodular a resposta inflamatória em um mamífero. A presente invenção também proporciona uma composição que compreende proteínas terapêuticas e/ou profiláticas e moléculas de oligossacarídeo para imunomodulação em sepse; e método para tratar e/ou evitar sepse, MODS (síndrome de disfunção de múltiplos órgãos) ou choque séptico em um mamífero.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201941053971 | 2019-12-26 | ||
PCT/IB2020/062459 WO2021130729A1 (en) | 2019-12-26 | 2020-12-26 | Therapeutic molecules for combating sepsis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022012789A2 true BR112022012789A2 (pt) | 2022-09-20 |
Family
ID=76574046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022012789A BR112022012789A2 (pt) | 2019-12-26 | 2020-12-26 | Homólogo de proteína, quito-oligossacarídeo, composição farmacêutica, método de tratamento ou prevenção, ácido nucleico sintético ou recombinante e uso de um homólogo de proteína |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230105103A1 (pt) |
EP (1) | EP4081223A4 (pt) |
KR (1) | KR20220132542A (pt) |
AU (1) | AU2020415493A1 (pt) |
BR (1) | BR112022012789A2 (pt) |
WO (1) | WO2021130729A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022185286A1 (en) * | 2021-03-05 | 2022-09-09 | Centre For Cellular And Molecular Platforms | Therapeutic and/or prophylactic anti-viral agent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1261264A (en) * | 1984-11-29 | 1989-09-26 | Shigeo Suzuki | Immunopotentiating agents and method |
JPS62138496A (ja) * | 1985-12-11 | 1987-06-22 | Ihara Chem Ind Co Ltd | キチンオリゴマ−の製造方法 |
US20020198139A1 (en) * | 2001-05-17 | 2002-12-26 | Deutschman Clifford S. | Method of preventing acute pulmonary cell injury |
-
2020
- 2020-12-26 AU AU2020415493A patent/AU2020415493A1/en active Pending
- 2020-12-26 KR KR1020227025947A patent/KR20220132542A/ko unknown
- 2020-12-26 WO PCT/IB2020/062459 patent/WO2021130729A1/en unknown
- 2020-12-26 US US17/789,381 patent/US20230105103A1/en active Pending
- 2020-12-26 BR BR112022012789A patent/BR112022012789A2/pt unknown
- 2020-12-26 EP EP20904502.0A patent/EP4081223A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4081223A1 (en) | 2022-11-02 |
EP4081223A4 (en) | 2024-03-27 |
KR20220132542A (ko) | 2022-09-30 |
WO2021130729A1 (en) | 2021-07-01 |
US20230105103A1 (en) | 2023-04-06 |
AU2020415493A1 (en) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
BR112017016336A2 (pt) | proteínas de ligação icos agonistas? | |
BR112017008165B8 (pt) | anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado | |
BR112018007422A2 (pt) | anticorpos anti-age e métodos de uso dos mesmos | |
BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
MX2017014730A (es) | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). | |
PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
Chow et al. | Human cathelicidin LL-37-derived peptide IG-19 confers protection in a murine model of collagen-induced arthritis | |
AR085281A1 (es) | Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso | |
BR112018071167A2 (pt) | entrega de beta-sarcoglicano e microrna-29 por vírus adenoassociado e tratamento de distrofia muscular | |
BR112018010160A8 (pt) | inibidor da c1 esterase humana recombinante e usos do mesmo | |
WO2016112208A3 (en) | Topical applications of kv1.3 channel blocking peptides to treat skin inflammation | |
BR112021023024A2 (pt) | Anticorpo contra claudina 18a2 e uso do mesmo | |
BRPI0510016A (pt) | vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina | |
BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
BR112021023957A2 (pt) | Peptídeos | |
BR112022012789A2 (pt) | Homólogo de proteína, quito-oligossacarídeo, composição farmacêutica, método de tratamento ou prevenção, ácido nucleico sintético ou recombinante e uso de um homólogo de proteína | |
BR112015018335A2 (pt) | Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas | |
BR112018008840A8 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
BR112018067747A2 (pt) | proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne | |
AR113134A1 (es) | Arni variante | |
BR112022003745A2 (pt) | Proteínas de fusão terapêuticas | |
EP4342534A3 (en) | Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury | |
BR112018071215A2 (pt) | peptídeo para uso no tratamento, melhora ou prevenção de osteoartrite | |
BR112017022390A2 (pt) | composição farmacêutica |